Aimmune Therapeutics, Inc. (AIMT) Q3 2019 Results Earnings Conference Call November 6, 2019 4:30 PM ET
Company Participants
DeDe Sheel - Vice President of Investor Relations
Eric Bjerkholt - Chief Financial Officer
Jayson Dallas - President and Chief Executive Officer
Andrew Oxtoby - Chief Commercial Officer
Conference Call Participants
Charles Duncan - Cantor Fitzgerald
Chris Raymond - Piper Jaffray
Justin Burns - RBC Capital Markets
Brian Skorney - Baird
Evan Seigerman - Credit Suisse
Corinne Jenkins - Goldman Sachs
Operator
Good day ladies and gentlemen, and welcome to the Aimmune Therapeutics Third Quarter Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. Thank you.
I would now like to turn the conference over to your host, Ms. DeDe Sheel, Vice President of Investor Relations. Please go ahead, madam.
DeDe Sheel
Thank you, Katrina. Good afternoon and thank you for joining us today to discuss Aimmune's third quarter 2019 financial results and operational highlights. Today's call is being webcast and a replay will be available on our corporate website at aimmune.com.
Joining me on the call today are Dr. Jayson Dallas, President and Chief Executive Officer; Andrew Oxtoby, Chief Commercial Officer; and Eric Bjerkholt, Chief Financial Officer. After our prepared remarks, we’ll open the call for Q&A.
Before we begin, I would like to remind you that during today's call and Q&A session, we will be making forward-looking statements. These forward-looking statements include Aimmune’s expectations regarding the potential benefits of PALFORZIA, including potential benefits for patients, care givers and allergists. Potential approval of PALFORZIA by the FDA and the EMA including approval timelines to potential commercial launch of PALFORZIA, including launch timelines to potential REMS for PALFORZIA, the potential receipt of
- Read more current AIMT analysis and news
- View all earnings call transcripts